semaglutide compounding pharmacy ban The FDA's Decision to Compounds: What You Need to Know FDA is moving to restrict

"Our approach emphasizes stewardship of the entire treatment continuum, from start through maintenance, with a clear clinical framework for when therapy can be safely reduced and, when appropriate, discontinued. Today, there is no clear standard for how long patients should stay on GLP-1s or how to safely come off

The addition of glucagon receptor activation increases energy expenditure and fat oxidation beyond what GLP-1 alone can achieve

Meanwhile, the GIP receptors enhance metabolic control and support improved glucose regulation

Researchers Analyzed Real-World Patient Outcomes The team used Optum Market Clarity, a US electronic health record and insurance claims database, to analyze patients who started liraglutide, semaglutide, or tirzepatide between January 2021 and June 2024